Who Grades the AI Models? | Ben Horowitz & Rayan Krishnan
a16z’s Erik Torenberg, Ben Horowitz, and Jennifer Li sit down with Vals founder and CEO Rayan Krishnan to discuss one of AI’s increasingly difficult problems: how do you actually measure whether a mod...
9 Sep 39min
OpenAI Researchers on the Future of Mathematical Reasoning
a16z Infra Partner Lisha Li sits down with OpenAI mathematicians Mehtaab Sawhney and Mark Sellke to discuss how quickly AI’s mathematical capabilities are advancing, what recent results reveal about m...
8 Sep 1h 5min
Can Open Source Keep AI Power From Concentrating?
MTS host Sophia Dew visits the Open Source AI Summit in San Francisco to ask researchers and founders across the AI stack a central question: can open source prevent AI power from concentrating in the...
7 Sep 8min
Your AI Doctor Is Coming | Julie Yoo
a16z General Partner Julie Yoo joins MTS host Sophia Dew to explain why she believes healthcare could benefit more from AI than almost any other industry, and why decades of slow technology adoption m...
6 Sep 27min
Aaron Levie on Why Open AI Wins
Box co-founder and CEO Aaron Levie joins MTS hosts Theo Jaffee and Sofia Puccini to make the case for open-weight AI, unpack the economics of open versus closed models, and explain why he believes mor...
5 Sep 31min
Fei Fei Li: The Race to Build World Models For AI
World Labs co-founders Fei-Fei Li, Justin Johnson, and Ben Mildenhall join a16z General Partner Martin Casado to discuss Atlas, their latest world model, and what it reveals about the pursuit of spati...
4 Sep 44min
The $100B Niches Hiding Inside Payments
Erik Torenberg is joined by a16z General Partner Alex Rampell and Affirm Co-Founder and CEO Max Levchin for a conversation on 25 years of fintech, from the early days of digital payments to the origin...
3 Sep 1h
Inside Moderna’s Personalized Cancer Vaccine
a16z General Partner Jorge Conde sits down with Moderna CEO Stéphane Bancel to discuss a major milestone for mRNA technology: positive Phase 3 results from Moderna and Merck’s individualized treatment...
2 Sep 40min
